C9098

Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Terminated September 30, 2022.

Notice

HCPCS C9098 terminated on September 30, 2022.

Short Description

Ciltacabtagene car pos t

HCPCS Coverage Code

C = Carrier judgment

HCPCS Action Code

N = No maintenance for this code

HCPCS Action Effective Date

October 01, 2022

HCPCS Code Added Date

July 01, 2022

HCPCS Termination Date

September 30, 2022

HCPCS Pricing Indicator Code

53 = Statute

HCPCS Multiple Pricing Indicator Code

A = Not applicable as HCPCS priced under one methodology

HCPCS Type Of Service Code

1 = Medical care

C9098

Notice

Short Description

HCPCS Coverage Code

HCPCS Action Code

HCPCS Action Effective Date

HCPCS Code Added Date

HCPCS Termination Date

HCPCS Pricing Indicator Code

HCPCS Multiple Pricing Indicator Code

HCPCS Type Of Service Code

HCPCS Anesthesia Base Unit Quantity